We report the synthesis of a small series of 6"-triazol-1-yl-substituted α-GalCer analogues by late-stage conversion of the 6"-OH to an azide group, copper-catalyzed azide-alkyne cycloaddition and final deprotection. When evaluated for their capacity to induce IL-2 secretion in vitro, all compounds proved equally potent or superior to α-GalCer. The S.A.R suggests that the improved antigenic activity is mainly triggered by the triazole functionalization in se. While the introduction of selected substitutuents at C-4 of this heterocyclic ring is tolerated, this generally fails to further improve antigenicity. 
Introduction
Invariant natural killer T cells (iNKT cells) are a unique lymphocyte population characterized by markers associated with both NK and conventional T cells. 1 Their semi-invariant T cell receptor (TCR) is encoded by an invariant Vα14-Jα18 chain in mice (homologous Vα24Jα18 chain in humans), preferentially paired with Vβ8.2, Vβ7 or Vβ2 (Vβ11 in humans).
Recognition of glycolipid antigens presented by the MHC class I-like protein CD1d and subsequent activation of these iNKT cells lead to a rapid release of copious amounts of proinflammatory and regulatory cytokines, including IFN-γ and IL-4. Hence they contribute to different immune responses against microorganisms, 2 tumors 3 and self-antigens. 4 Since iNKT cells bridge the innate and adaptive immune system, they represent an attractive target for immunotherapeutics.
The most extensively studied ligand for iNKT cells is KRN7000 (1, Figure 1 ), also referred to as α-galactosylceramide (α-GalCer), a structurally optimized compound derived from extracts of the marine sponge Agelas Mauritianus. 5 Its potential in the treatment of several diseases such as certain tumors, infections and autoimmune diseases has been related to the activation of iNKT cells 6 and downstream activation of other immune cells such as NK 7 and B cells. 4 is replaced by a CH 2 group. 12 S.A.R. studies revealed a wide variety of possible alterations in the ceramide part resulting in a shifted cytokine profile. By contrast, successful modifications of the galactose moiety are rather scarce and mostly limited to the 6"-position. 6"-modifications were first reported by the group of Savage, who showed that analogues containing different fluorophores 13 or an acetamide group 14 at this position were still able to activate iNKT cells similar to α-GalCer. This finding led different groups to explore alternative C-6"-modifications such as pegylation, 15 O-methylation (RCAI-6) and 6"-deoxygenation. 16 Previously, we demonstrated that a C-6"-naphthylurea derivative (NU-α-GalCer, 4) exhibits marked anti-tumor effects in a mouse B16 melanoma model. 17 A crystal structure of NU-α-GalCer complexed to CD1d and the TCR allowed relating this response to the induction of a third anchor in CD1d by the naphthylurea group, thereby probably enhancing the affinity for CD1d. Encouraged by these findings, we decided to investigate alternative C-6"-modifications. Here, we describe the synthesis and preliminary biological evaluation of a small series of α-GalCer derivatives containing different 4-substituted triazol-1-yl moieties at the C-6"-position. Figure 1 . Structures of KRN7000, OCH, α-C-GalCer and NU-α-GalCer and PhA-α-GalCer.
The copper-catalyzed azide-alkyne cycloaddition (CuAAC) variant of Huisgen's 1,3-dipolar cycloaddition provides an easy and reliable method to link two building blocks via a 1,2,3-triazole moiety. Besides being a rigid linking unit, the 1,4-disubstituted triazole also possesses desirable pharmacological properties. 18 It is metabolically stable and, due to its high aromatic stabilization, resistant towards acid and basic hydrolysis and towards reductive and oxidation conditions. It has a large dipole moment (about 5 D) and is able to participate in hydrogen bond formation, dipole-dipole and π-stacking interactions. Since the aforementioned crystal structure revealed an extra hydrogen bond between the urea carbonyl oxygen of NU-α-GalCer and Thr159 of CD1d, the capacity of a triazole moiety to act as H-bonding acceptor is most appealing. Moreover, a 1,4-disubstituted triazole group is suggested as a bioisostere of a trans-amide bond, which is interesting in view of the distinct Th1 profile of α-GalCer analogues with aromatic amides on C-6" such as phenyl-substituted amide 5. 19 Hence, its corresponding triazole compound 9c is synthesized and evaluated for comparative reasons. 
Biological Evaluation
To assess the antigenic activity of the final compounds, bone marrow dendritic cells (BMDCs) were loaded during 20 hours with 100 ng/mL glycolipid. After 16 hours of coculture with 2C12 cells (iNKT cell hybridoma), IL-2 secretion was determined by ELISA.
9a-f
showed an efficacy to release IL-2 that was higher or comparable to α-GalCer ( Figure 3 ).
The analogues in which a butyl (9b) or phenyl (9c) substitituent is directly attached to the triazole ring tend to induce the highest IL-2 secretion. Strikingly, the response of phenylsubstituted triazole 9c contrasts with the in vitro results obtained by Besra and co-workers, where a remarkably reduced iNKT cell stimulatory activity is observed for this compound.
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A possible explanation for this discrepancy is the direct incubation of glycolipids, BMDCs and iNKT cell hybridomas in their assay, while we used glycolipid-loaded BMDCs.
Introduction of varying linker lengths between the triazole and the phenyl moieties doesn't seem to significantly influence the antigenic activity. Hence we speculated that the mere presence of a triazol-1-yl ring at position 6" suffices to cause a superior antigenic activity than α-GalCer. Affirmatively, dendritic cells (DCs) loaded with the unsubstituted triazole analogue 9a were even better in stimulating iNKT cells to release IL-2. This is consistent with the potent iNKT cell activity of the precursor azide reported in the publication of Besra and coworkers. 21 The IL-2 secretion induced by butyl containing analogue 9b is in line with the alkyl-substituted triazoles of Besra, where the one with an octyl chain is far more active than the one with a longer undecyl chain. Contradictory to the docking experiment, however, these data indicate that 1,4-substitution of the triazole moiety doesn't interfere in the interaction with CD1d and the TCR, provided that the attached group doesn't exceed a certain size. 
Conclusions
In summary, a series of phenyl-substituted C-6"-triazolyl α-GalCer analogues as well as a butyl-and non-substituted one have been synthesized using a copper-catalyzed azide-alkyne cycloaddition reaction. Evaluation of the in vitro IL-2 secretion induced by these compounds reveals them as potent iNKT cell stimulating ligands. We suggest that the observed increase in antigenic activity is mainly due to the triazole functionalization whereby further substitutions at C-4 of this heterocycle with small groups is tolerated.
Experimental Section Chemical Synthesis
Precoated Macherey-Nagel SIL G/UV 254 plates were used for TLC, and spots were examined 
General procedure for CuAAC click reaction
To a solution of azide 7 (80 mg, 0.06 mmol) in DMF (2 mL)was added the appropriate alkyne, sodium ascorbate and copper(II)sulfate. The reaction mixture was stirred for 20 minutes at 70 °C in the microwave. After extraction with EtOAc, the organic phase was washed with brine and dried over Na 2 SO 4 , followed by evaporation of the solvent.
Purification by column chromatography (hexanes/EtOAc: 7.5/2.5) afforded the desired triazoles 8b (74%), 8c (60%), 8d (95%), 8e (80%) and 8f (97%) . 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-benzyltriazol-1-yl)-α-Dgalactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8d)

(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(triazol-1-yl)-α-Dgalactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8a).
Azide 7 was dissolved in vinyl acetate and stirred at 120 °C in the microwave. After 6 h, the reaction mixture was evaporated to dryness. Purification by column chromatography (hexanes/EtOAc: 7.5/2.5) afforded the desired triazole 8a (93 mg, 71%). 
General procedure for debenzylation
A solution of the protected triazole (0.06 mmol) in CHCl 3 (0.4 mL) and EtOH (1.2 mL) was hydrogenated under atmospheric pressure in the presence of palladium black (10 mg). Upon reaction completion, the mixture was diluted with pyridine and filtered through celite. The filter cake was rinsed with CHCl 3 and EtOH and the filtrate was evaporated to dryness. After purification by column chromatography (CH 2 Cl 2 /MeOH: 8/2), final compounds 9a (31%), 9b
(50%), 9c (40%), 9d (22%), 9e (31%) and 9f (53%) were obtained as white powders. 
